Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
361. |
ECCT/22/08/03 | NeoSep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of clinically diagnosed neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Christina Wesonga Obiero 2. James Alexander Berkley Site(s) in Kenya 1. Kilifi County Hospital, KEMRI- Wellcome Trust Research Programme (KWTRP) (Kilifi county) |
21-12-2022 |
View |
362. |
ECCT/22/10/01 | AGYW Pharmacy PrEP Delivery Enhancing PrEP outcomes among Kenyan adolescent girls and young women with a novel pharmacy-based PrEP delivery platform |
Principal Investigator(s) 1. ELIZABETH BUKUSI Site(s) in Kenya KEMRI RCTP Lumumba, Kisumu |
23-12-2022 |
View |
363. |
ECCT/22/10/02 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Janet N Oyieko Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Strathmore University Medical Centre (Nairobi City county) |
10-02-2023 |
View |
364. |
ECCT/22/09/02 | LISA Trial Levonorgestrel intrauterine system effects on hemoglobin and serum ferritin among anemic women in Kenya: An open label randomized trial to compare with an oral contraceptive regimen that provides supplemental ferrous fumarate tablets |
Principal Investigator(s) 1. Faith Mugure Thuita Site(s) in Kenya Kangemi Health Centre |
23-02-2023 |
View |
365. |
ECCT/22/10/05 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
26-02-2023 |
View |
366. |
ECCT/22/11/04 | YWF:03 YWF:03: A PHASE III, MULTICENTER, DOUBLE BLIND, RANDOMIZED STUDY OF SII YELLOW FEVER VACCINE TO COMPARE SAFETY AND IMMUNOGENICITY WITH STAMARIL® |
Principal Investigator(s) 1. Videlis Nduba 2. Otieno Walter Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
26-02-2023 |
View |
367. |
ECCT/22/11/02 | UNCPM 22120 5-FU Study UNCPM 22120: Safety of adjuvant, self-administered intravaginal 5-fluorouracil (5-FU) cream following cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3) treatment among HIV-positive women in Kenya: A pilot study |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Chemtai Mungo Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) |
01-03-2023 |
View |
368. |
ECCT/23/01/05 | IMPALA Study Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open-Label Randomized Controlled Trial |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
14-03-2023 |
View |
369. |
ECCT/22/12/01 | HIV & Tobacco Cessation Study Integrating Tobacco use cessation into HIV care and Treatment Clinics in Ministry of Health Facilities in Kisumu County, Kenya |
Principal Investigator(s) 1. Elizabeth Bukusi Site(s) in Kenya KEMRI-RCTP |
16-03-2023 |
View |
370. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
12-04-2023 |
View |